EAEU and Regional Recognition of Iranian Medical Device Registrations

1. Key takeaways

Paragraph B of Article 72 of the Seventh National Development Plan Law lists regional countries, countries of the shared civilisational sphere and members of the Eurasian Economic Union as the priority directions for mutual recognition negotiations. GRZAN’s assessment: the Iranian registration certificate is turning from a cost item into an asset item — for companies that are simultaneously building a presence in the Eurasian Economic Union (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan), the way the Iranian dossier is organised directly affects the preparation cost of the subsequent markets. The value is realised not only if formal recognition agreements are signed, but already in the reuse of the underlying evidence, which is why the dossier structure matters now rather than at the moment an agreement appears. The dossier structure is also the part of this shift that companies control directly, which makes it the part worth acting on immediately.

2. Legal basis

1. Law on the Seventh National Development Plan of the Islamic Republic of Iran, in force for the Iranian calendar years 1403–1407, Chapter 14, Article 72, Paragraph B: bilateral and multilateral negotiations are to be prioritised with regional countries, countries of the shared civilisational sphere and members of the Eurasian Economic Union, working for these countries to accept Iranian-registered active pharmaceutical ingredients, medicines, consumables and medical devices, and to issue registration certificates, market access licences and joint production quality certificates; the deadline is the end of year 2 of the Plan. The three named instruments — certificate, licence and quality certificate — together define what recognition is intended to deliver.
2. Preamble to Article 72 of the same law: the annual export target for medical devices is to exceed 1 billion euros; the annual revenue target for medical tourism is 6 billion euros; the annual revenue target for international students of medicine is to exceed 700 million euros. Taken together, the targets show that the outward-facing health economy is intended as a measurable programme with multiple revenue channels, of which device exports are one.
3. Iranian medical device industry base: Iran has more than 2,500 medical device manufacturing enterprises producing over 1,800 types of devices — see the health industry overview by the Investment Advisory Center of the Tehran Chamber of Commerce; this is a practical estimate, and the figures vary with the statistical year. The scale explains why mutual recognition is a two-way proposition rather than a one-way concession, and why the industry statistics behind it should be tracked periodically, since the competitive picture moves with them.

3. Expert insights

Insight one: mutual recognition of dossiers comes before mutual recognition of certificates. Even while certificate-level recognition has not yet landed, dossiers organised according to internationally accepted structures can themselves be reused across multiple markets. This is value companies can realise today, without waiting for recognition agreements to be signed — the evidence chain, the STED-style structure and the risk documentation transfer immediately, even if the certificate itself does not, and the marginal cost of the next market falls with every market entered this way. Each subsequent market entered with a reused dossier also raises the quality of the original file, because reuse exposes gaps that a single-market submission would have left hidden.

Insight two: the joint production quality certificate is an underrated instrument. Beyond the registration certificate and the market access licence, Paragraph B explicitly mentions the joint production quality certificate. This provides an institutional vehicle for the model of manufacturing in Iran and exporting to the region, and it can be designed together with the localisation strategy for responding to import blocking, so that one production arrangement serves both purposes instead of being justified twice under two separate frameworks.

Insight three: Iran’s own industrial scale makes recognition bidirectional. More than 2,500 domestic manufacturing enterprises mean that Iran is both a potential market and a potential competitor. When assessing spillover value, companies should also assess the possibility of Iranian domestic products flowing outward through the same mutual recognition channel, competing in the very markets the company is targeting, because a channel that opens for one direction of trade does not stay closed for the other.

4. Practical recommendations

1. Organise the dossier once, reuse it across markets: build the evidence chain on the STED structure and international standards, reducing the marginal cost of every subsequent market entry and keeping the file in a state where it can be submitted elsewhere without reconstruction, with versioning so reuse does not fork it into inconsistent copies.
2. Design localisation and regional export together: consider the local production option for import blocking and the joint production quality certificate route in one design, so the two reinforce each other and the production footprint serves the regional strategy as well as the domestic gate.
3. Track the negotiation progress: establish a tracking mechanism for the negotiation outcomes under Paragraph B of Article 72, so that the first markets to land can be captured early and the company is not learning about a concluded arrangement from its competitors’ actions.
4. Assess competitive spillover: evaluate in parallel the possibility of Iranian domestic products flowing outward through the recognition channel, since the same door opens in both directions and the competitive picture of the target markets changes with it, and feed the findings back into the regional map.

5. Verification checklist

• □ The Iranian submission dossier has been organised in a structure reusable across multiple markets
• □ A list of priority markets across the three categories — regional countries, civilisational sphere, Eurasian Economic Union — has been drawn up
• □ The localisation option and the joint production quality certificate route have been designed together
• □ A tracking mechanism for the negotiation progress under Paragraph B of Article 72 is in place
• □ The competitive impact of Iranian domestic products flowing outward has been assessed

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages adverse event reporting and recall coordination with IFDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com